A Robust and Efficient Production and Purification Procedure of Recombinant Alzheimers Disease Methionine-Modified Amyloid-β Peptides

An improved production and purification method for Alzheimer's disease related methionine-modified amyloid-β 1-40 and 1-42 peptides is proposed, taking advantage of the formation of inclusion body in Escherichia coli. A Thioflavin-S assay was set-up to evaluate inclusion body formation during g...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 8; p. e0161209
Main Authors Hoarau, Marie, Malbert, Yannick, Irague, Romain, Hureau, Christelle, Faller, Peter, Gras, Emmanuel, André, Isabelle, Remaud-Siméon, Magali
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An improved production and purification method for Alzheimer's disease related methionine-modified amyloid-β 1-40 and 1-42 peptides is proposed, taking advantage of the formation of inclusion body in Escherichia coli. A Thioflavin-S assay was set-up to evaluate inclusion body formation during growth and optimize culture conditions for amyloid-β peptides production. A simple and fast purification protocol including first the isolation of the inclusion bodies and second, two cycles of high pH denaturation/ neutralization combined with an ultrafiltration step on 30-kDa cut-off membrane was established. Special attention was paid to purity monitoring based on a rational combination of UV spectrophotometry and SDS-PAGE analyses at the various stages of the process. It revealed that this chromatography-free protocol affords good yield of high quality peptides in term of purity. The resulting peptides were fully characterized and are appropriate models for highly reproducible in vitro aggregation studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current address: Unité Fonctionnalité et Ingénierie des Protéines, CNRS, Université de Nantes, Nantes, France
Competing Interests: The authors have declared that no competing interests exist.
These authors also contributed equally to this work.
Current address: Institut de Chimie, UMR 7177, Université de Strasbourg, Strasbourg, France
Conceptualization: CH PF EG IA MRS. Funding acquisition: EG CH IA MRS. Investigation: MH. Methodology: MH YM RI MRS. Project administration: EG MRS. Supervision: EG MRS. Validation: YM RI MRS. Visualization: MH. Writing - original draft: MH. Writing - review & editing: MH YM RI CH PF EG IA MRS.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0161209